These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 35850711)

  • 21. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study.
    Sun PL; Li B; Ye QF
    Int J Colorectal Dis; 2012 Oct; 27(10):1325-32. PubMed ID: 22430888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
    Gao YH; Lin JZ; An X; Luo JL; Cai MY; Cai PQ; Kong LH; Liu GC; Tang JH; Chen G; Pan ZZ; Ding PR
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1153-60. PubMed ID: 25442042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial.
    Fan WH; Wang FL; Lu ZH; Pan ZZ; Li LR; Gao YH; Chen G; Wu XJ; Ding PR; Zeng ZF; Wan DS
    Chin J Cancer; 2015 Jun; 34(9):394-403. PubMed ID: 26111932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 25. [Feasibility study on Xelox (capecitabine plus oxapliplatin) in the volumetric modulated arc therapy (VMAT)-based preoperative chemoradiotherapy for locally advanced rectal cancer].
    Xiao L; Huang R; You K; Chang H; Qiu B; Xiao W; Chen L; Gao Y; Liu M
    Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Mar; 17(3):219-24. PubMed ID: 24671807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retrospective Comparison of mFOLFOXIRI With XELOX/SOX as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer.
    Kodama H; Terazawa T; Ishizuka Y; Yukami H; Aoki M; Miyamoto T; Yamaguchi T; Shimamoto F; Kii T; Goto M; Hamamoto H; Osumi W; Yamamoto M; Tanaka K; Okuda J; Uchiyama K; Higuchi K
    In Vivo; 2021; 35(2):977-985. PubMed ID: 33622892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study.
    Okuyama T; Sameshima S; Takeshita E; Yoshioka R; Yamagata Y; Ono Y; Tagaya N; Noie T; Oya M
    World J Surg Oncol; 2018 Jun; 16(1):105. PubMed ID: 29871650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.
    Garcia-Aguilar J; Patil S; Gollub MJ; Kim JK; Yuval JB; Thompson HM; Verheij FS; Omer DM; Lee M; Dunne RF; Marcet J; Cataldo P; Polite B; Herzig DO; Liska D; Oommen S; Friel CM; Ternent C; Coveler AL; Hunt S; Gregory A; Varma MG; Bello BL; Carmichael JC; Krauss J; Gleisner A; Paty PB; Weiser MR; Nash GM; Pappou E; Guillem JG; Temple L; Wei IH; Widmar M; Lin S; Segal NH; Cercek A; Yaeger R; Smith JJ; Goodman KA; Wu AJ; Saltz LB
    J Clin Oncol; 2022 Aug; 40(23):2546-2556. PubMed ID: 35483010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensified Total Neoadjuvant Therapy
    DE Felice F; Musio D; Iafrate F; Caponnetto S; Picone V; D'Ambrosio G; Magliocca FM; Tozzi F; DE Toma G; Tombolini V; Cortesi E
    Anticancer Res; 2022 Feb; 42(2):991-1000. PubMed ID: 35093899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
    Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
    Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
    Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer.
    Valentini V; Gambacorta MA; Cellini F; Aristei C; Coco C; Barbaro B; Alfieri S; D'Ugo D; Persiani R; Deodato F; Crucitti A; Lupattelli M; Mantello G; Navarria F; Belluco C; Buonadonna A; Boso C; Lonardi S; Caravatta L; Barba MC; Vecchio FM; Maranzano E; Genovesi D; Doglietto GB; Morganti AG; La Torre G; Pucciarelli S; De Paoli A
    Radiother Oncol; 2019 May; 134():110-118. PubMed ID: 31005204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial).
    Kondo K; Matsusaka S; Ishihara S; Horie H; Uehara K; Oguchi M; Murafushi K; Ueno M; Mizunuma N; Shimbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Fujii M; Nakajima T
    Radiother Oncol; 2019 May; 134():199-203. PubMed ID: 31005216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: long-term results of a phase III randomized controlled trial.
    Tian Y; Yang P; Guo H; Liu Y; Zhang Z; Ding P; Zheng T; Deng H; Ma W; Li Y; Fan L; Zhang Z; Wang D; Zhao X; Tan B; Liu Y; Zhao Q
    Int J Surg; 2023 Dec; 109(12):4000-4008. PubMed ID: 37678277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer.
    Azria D; Doyen J; Jarlier M; Martel-Lafay I; Hennequin C; Etienne P; Vendrely V; François E; de La Roche G; Bouché O; Mirabel X; Denis B; Mineur L; Berdah J; Mahé M; Bécouarn Y; Dupuis O; Lledo G; Seitz J; Bedenne L; Gourgou-Bourgade S; Juzyna B; Conroy T; Gérard J
    Ann Oncol; 2017 Oct; 28(10):2436-2442. PubMed ID: 28961836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer.
    Dellas K; Höhler T; Reese T; Würschmidt F; Engel E; Rödel C; Wagner W; Richter M; Arnold D; Dunst J
    Radiat Oncol; 2013 Apr; 8():90. PubMed ID: 23587311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
    Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
    Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial.
    Jia R; Shan T; Zheng A; Zhang Y; Lu P; Zhang G; Wang F; Xu Z; Zheng G; Tang D; Zhang W; Li W; Li R; Guo Y; Liu L; Luo X; Zheng Y; Chang Z; Wang Q; Wang X; Yuan X; Kong G; Li S; Yang R; Zhou D; Ren J; Yin W; Li J; Zhang J; Wang Z; Sheng M; Xu B; Li L; Liu X; Lu Z; Wan L; Zhou F; Gao S
    J Clin Oncol; 2024 Jul; 42(20):2436-2445. PubMed ID: 38710003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.